Literature DB >> 28850686

Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.

Xiaoyu Shi1, Yanfei Peng2, Xiaoling Du1, Haitao Liu3, Helmut Klocker4, Qimei Lin1, Jiandang Shi1, Ju Zhang1.   

Abstract

BACKGROUND: Epithelial-to-mesenchymal transition (EMT) is involved in pathogenesis of human benign prostatic hyperplasia (BPH). Estrogenic signaling pathways may stimulate the induction of EMT. However, the details of estradiol (E2) and estrogen receptors (ERs) effects on EMT, as well as E2-induced modulation of benign prostatic epithelial cell phenotype in vitro have not been completely clarified.
METHODS: The effects of E2 on EMT markers and cytokeratins (CKs) expression were evaluated in benign epithelial cell lines BPH-1 and RWPE-1, which were cultured both in two-dimensional (2D) culture and three-dimensional (3D) culture model using hanging drop technique or 3D Matrigel model. ER antagonist, ICI182,780, was used to confirm the regulatory effects of E2 on EMT and phenotypic modulation. In 3D culture, immunohistochemical stainings were performed to detect the specific phenotype of cells that underwent EMT in acinar-like spheroids formed by RWPE-1. To illustrate the exact function of ERs in E2-induced EMT and phenotypic modulation, specific short interfering RNAs (siRNAs), and agonists were used to knockdown or activate individual ERs, respectively.
RESULTS: E2-induced EMT was observed both in 2D and 3D culture, with related regulation of EMT markers expression at both mRNA and protein level. In addition, E2 down-regulated luminal cell type markers CK18 and CK8 and up-regulated basal cell type markers CK5 and CK14. E2 also increased intermediate type markers CK15 and CK17, while it attenuated CK19 in 3D culture. ICI182,780 blocked E2-induced EMT and cell phenotypic switching. In 3D Matrigel culture, Vimentin was co-expressed with ERα and CK17, as well as with SMemb, which is related to cell status switching and proliferation. Knockdown of ERα but not GPR30 inhibited EMT, while ERβ knockdown facilitated EMT process. Knockdown of ERα blocked E2-induced EMT both in RWPE-1 and BPH-1. MRNA expression of EMT markers was stimulated by ERα-specific agonist PPT and inhibited by ERβ-specific agonist DPN.
CONCLUSIONS: Estrogenic effect mediated by ERα can promote EMT. E2 is also an inductive factor of cell phenotypic switching. Cell type modulation is associated with E2-induced EMT in benign prostatic epithelial cells. Taken together the results support a contribution of estrogens to the pathogenesis of BPH in elderly men.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  benign prostatic hyperplasia; epithelial-to-mesenchymal transition; estradiol; estrogen receptor α; three-dimensional cell culture

Mesh:

Substances:

Year:  2017        PMID: 28850686     DOI: 10.1002/pros.23404

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

Review 1.  Epidemiology and treatment modalities for the management of benign prostatic hyperplasia.

Authors:  Soum D Lokeshwar; Benjamin T Harper; Eric Webb; Andre Jordan; Thomas A Dykes; Durwood E Neal; Martha K Terris; Zachary Klaassen
Journal:  Transl Androl Urol       Date:  2019-10

2.  Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells.

Authors:  Ekapot Singsuksawat; Chanitra Thuwajit; Komgrid Charngkaew; Peti Thuwajit
Journal:  Cancer Cell Int       Date:  2018-02-20       Impact factor: 5.722

3.  Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer.

Authors:  Yongmei Shen; Jiasong Cao; Zhixian Liang; Qimei Lin; Jianxi Wang; Xu Yang; Ran Zhang; Jiaojiao Zong; Xiaoling Du; Yanfei Peng; Ju Zhang; Jiandang Shi
Journal:  Cell Commun Signal       Date:  2019-05-23       Impact factor: 5.712

4.  Estradiol Induces Epithelial to Mesenchymal Transition of Human Glioblastoma Cells.

Authors:  Ana M Hernández-Vega; Aylin Del Moral-Morales; Carmen J Zamora-Sánchez; Ana G Piña-Medina; Aliesha González-Arenas; Ignacio Camacho-Arroyo
Journal:  Cells       Date:  2020-08-21       Impact factor: 6.600

5.  LncRNA DIO3OS regulated by TGF-β1 and resveratrol enhances epithelial mesenchymal transition of benign prostatic hyperplasia epithelial cells and proliferation of prostate stromal cells.

Authors:  Yanbo Chen; Hui Xu; Chong Liu; Meng Gu; Ming Zhan; Qi Chen; Zhong Wang
Journal:  Transl Androl Urol       Date:  2021-02

6.  The HeyL-Aromatase Axis Promotes Cancer Stem Cell Properties by Endogenous Estrogen-Induced Autophagy in Castration-Resistant Prostate Cancer.

Authors:  Qimei Lin; Jiasong Cao; Xiaoling Du; Kuo Yang; Yongmei Shen; Weishu Wang; Helmut Klocker; Jiandang Shi; Ju Zhang
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

7.  Therapeutic Effects of 25-Hydroxyvitamin D on the Pathological Process of Benign Prostatic Hyperplasia: An In Vitro Evidence.

Authors:  Yanbo Chen; Hui Xu; Chong Liu; Meng Gu; Qi Chen; Ming Zhan; Zhong Wang
Journal:  Dis Markers       Date:  2021-10-11       Impact factor: 3.434

8.  CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation.

Authors:  Qimei Lin; Jiasong Cao; Xiaoling Du; Kuo Yang; Xu Yang; Zhixian Liang; Jiandang Shi; Ju Zhang
Journal:  Cell Commun Signal       Date:  2022-03-15       Impact factor: 5.712

9.  MicroRNA-340 Inhibits Epithelial-Mesenchymal Transition by Impairing ROCK-1-Dependent Wnt/β-Catenin Signaling Pathway in Epithelial Cells from Human Benign Prostatic Hyperplasia.

Authors:  Si-Yang Chen; Yuan Du; Jian Song
Journal:  Chin Med J (Engl)       Date:  2018-08-20       Impact factor: 2.628

Review 10.  Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate Cancer.

Authors:  Erika Di Zazzo; Giovanni Galasso; Pia Giovannelli; Marzia Di Donato; Antonio Bilancio; Bruno Perillo; Antonio A Sinisi; Antimo Migliaccio; Gabriella Castoria
Journal:  Cancers (Basel)       Date:  2019-09-23       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.